Ablative Solutions, Inc., a company pioneering new approaches to the treatment of hypertension, today announced the completion of the fourth tranche of its Series D financing round, resulting in $91.4 million in aggregate proceeds to the Company from the Series D financing round. Gilde Healthcare, BioStar Capital, Invus Opportunities and an undisclosed strategic corporate investor led the multi-tranched Series D round of financing.

The Company is currently enrolling patients in the TARGET BP I pivotal trial to evaluate safety and efficacy in the treatment of patients with uncontrolled hypertension in conjunction with antihypertensive medications. Ablative Solutions, Inc., based in Wakefield, MA, was founded in 2011 with a vision to address the unmet need of hypertension.

Wakefield

Ablative Solutions

Ablative Solutions, Inc. Announces Completion Of The Fourth Tranche Of Its Series D Preferred Financing Round For Unique Therapeutic Approach To Treating Uncontrolled Hypertension

Ablative Solutions, Inc. Announces Completion Of The Fourth Tranche Of Its Series D Preferred Financing Round For Unique Therapeutic Approach To Treating Uncontrolled Hypertension

Description

Company Information